You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for ROFLUMILAST


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ROFLUMILAST

Average Pharmacy Cost for ROFLUMILAST

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
ROFLUMILAST 250 MCG TABLET 72205-0201-11 2.40210 EACH 2025-01-22
ROFLUMILAST 250 MCG TABLET 68382-0624-30 2.40210 EACH 2025-01-22
ROFLUMILAST 250 MCG TABLET 68382-0624-83 2.40210 EACH 2025-01-22
ROFLUMILAST 250 MCG TABLET 31722-0676-32 2.40210 EACH 2025-01-22
ROFLUMILAST 250 MCG TABLET 68382-0624-31 2.40210 EACH 2025-01-22
ROFLUMILAST 250 MCG TABLET 31722-0676-36 2.40210 EACH 2025-01-22
ROFLUMILAST 250 MCG TABLET 42571-0369-83 2.40210 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for ROFLUMILAST

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
ZORYVE 0.3% CREAM,TOP Arcutis Biotherapeutics, Inc. 80610-0130-60 60GM 616.67 10.27783 GM 2024-01-01 - 2028-01-14 Big4
ZORYVE 0.3% CREAM,TOP Arcutis Biotherapeutics, Inc. 80610-0130-60 60GM 812.56 13.54267 GM 2024-01-01 - 2028-01-14 FSS
ZORYVE 0.3% CREAM,TOP Arcutis Biotherapeutics, Inc. 80610-0130-60 60GM 842.62 14.04367 GM 2024-02-01 - 2028-01-14 FSS
ZORYVE 0.3% FOAM,TOP Arcutis Biotherapeutics, Inc. 80610-0430-60 60GM 642.25 10.70417 GM 2024-02-01 - 2028-01-14 FSS
ZORYVE 0.3% CREAM,TOP Arcutis Biotherapeutics, Inc. 80610-0130-60 60GM 597.78 9.96300 GM 2023-01-15 - 2028-01-14 Big4
ZORYVE 0.3% FOAM,TOP Arcutis Biotherapeutics, Inc. 80610-0430-60 60GM 619.16 10.31933 GM 2024-04-01 - 2028-01-14 Big4
ZORYVE 0.3% CREAM,TOP Arcutis Biotherapeutics, Inc. 80610-0130-60 60GM 812.56 13.54267 GM 2023-01-15 - 2028-01-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Roflumilast

Market Overview

Roflumilast, a phosphodiesterase-4 (PDE-4) inhibitor, has been gaining significant traction in the pharmaceutical market, particularly for its applications in treating chronic obstructive pulmonary disease (COPD) and increasingly for other conditions like atopic dermatitis and psoriasis.

Market Size and Growth Projections

The global Roflumilast market is anticipated to experience substantial growth over the forecast period from 2023 to 2030. Here are some key projections:

  • The market size is expected to grow from approximately USD 1.4 billion in 2023 to USD 2.54 billion by 2030, at a Compound Annual Growth Rate (CAGR) of around 8.9%[3].
  • Another report predicts the market will grow from USD 1523.2 million in 2024 to USD 2526.6 million by 2030, with a CAGR of 8.8% during the forecast period[2].

Segmentation and Applications

The Roflumilast market is segmented based on several factors:

By Type

  • The market is categorized into capsules and tablets, with both forms experiencing demand due to their convenience and efficacy[1][3].

By Application

  • The primary applications include hospitals, clinics, and other healthcare settings. The drug is predominantly used for treating COPD but is also being explored for atopic dermatitis and psoriasis[1][3].

Geographical Segmentation

  • The market is divided into regions such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. Each region presents unique growth opportunities and challenges[1][3].

Key Drivers and Restraints

Drivers

  • Increasing prevalence of COPD and other respiratory diseases is a significant driver for the Roflumilast market.
  • The drug's efficacy in treating moderate-to-severe psoriasis and atopic dermatitis, as evidenced by clinical trials, is expanding its market potential[5][4].
  • Generic versions of Roflumilast becoming available could make the drug more accessible and affordable, further boosting demand[5].

Restraints

  • Adverse events such as transient gastrointestinal symptoms, weight loss, headache, and insomnia may impact patient compliance and market growth.
  • Regulatory hurdles and competition from other treatments could also pose challenges[5].

Competitive Landscape

The Roflumilast market is characterized by a diverse set of players, including:

  • Alkem Laboratories
  • Astra Zeneca
  • Beltapharm Spa
  • Breckenridge Pharma
  • Hetero Drugs
  • KMS Health Center
  • Micro Labs
  • MS Pharma
  • MSN Laboratories
  • Viatris
  • Orchid Pharma
  • Orifarm Group
  • Precise Group
  • Takeda Pharmaceutical
  • Torrent Group[1][3].

These companies are profiled based on their product offerings, financial performance, market positioning, and strategic initiatives.

Price Projections and Revenue

Revenue Projections

  • The global Roflumilast market is projected to reach USD 2.54 billion by 2030, indicating a significant increase in revenue over the forecast period[3].

Price Trends

  • The price of Roflumilast is expected to remain competitive, especially with the entry of generic versions. However, the exact price trends will depend on regional market dynamics, regulatory environments, and the strategies of key players[2][3].

Regional Market Insights

North America and Europe

  • These regions are expected to be major contributors to the Roflumilast market due to high healthcare spending and a strong presence of key pharmaceutical companies[2][3].

Asia-Pacific

  • This region is anticipated to show rapid growth due to increasing healthcare infrastructure and a large patient population suffering from COPD and other respiratory diseases[1][3].

Clinical Trials and New Indications

Atopic Dermatitis

  • Arcutis Biotherapeutics' Roflumilast has shown promising results in Phase III trials for atopic dermatitis, with projected sales of $80 million by 2030. This new indication is expected to expand the market significantly[4].

Psoriasis

  • Clinical trials have demonstrated the efficacy and safety of oral Roflumilast in treating moderate-to-severe psoriasis, offering an alternative to established systemic treatments[5].
"Following such a fantastic result, GlobalData expects Arcutis Biotherapeutics’ roflumilast to enter the US atopic dermatitis (AD) market by Q2 2024, followed by the 5EU* in Q2 2025. It is projected to bring the company total sales of $80 million by 2030."[4]

Key Takeaways

  • The Roflumilast market is poised for significant growth driven by increasing demand for COPD treatments and new indications in atopic dermatitis and psoriasis.
  • The market is expected to reach USD 2.54 billion by 2030, growing at a CAGR of around 8.9%.
  • Generic versions and expanding applications will play crucial roles in market expansion.
  • Key players are focusing on strategic initiatives to maintain market share and capitalize on emerging opportunities.

Frequently Asked Questions (FAQs)

Q: What is the primary use of Roflumilast? A: Roflumilast is primarily used for treating severe chronic obstructive pulmonary disease (COPD).

Q: What are the new indications for Roflumilast? A: Roflumilast is being explored for treating atopic dermatitis and moderate-to-severe psoriasis.

Q: Who are the key players in the Roflumilast market? A: Key players include Alkem Laboratories, Astra Zeneca, Beltapharm Spa, Breckenridge Pharma, and others.

Q: What is the projected market size of Roflumilast by 2030? A: The market is expected to reach approximately USD 2.54 billion by 2030.

Q: What is the CAGR of the Roflumilast market from 2023 to 2030? A: The market is expected to grow at a CAGR of around 8.9% during the forecast period.

Cited Sources:

  1. Market Research Intellect - Global Roflumilast Market Size, Scope And Forecast Report[1]
  2. QYResearch - Global Roflumilast Market Insights, Forecast to 2030[2]
  3. Verified Market Reports - Roflumilast Market Size, Share, Scope, Trends And Forecast 2030[3]
  4. GlobalData - Arcutis's roflumilast estimated to bring $80 million in sales by 2030 following promising clinical trial results[4]
  5. The Lancet - Efficacy and safety of oral roflumilast for moderate-to-severe plaque psoriasis[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.